Difference between revisions of "Team:DTU-Denmark/Integrated Human Practices"

 
(15 intermediate revisions by 3 users not shown)
Line 2: Line 2:
 
{{DTU-Denmark/mainCSS}}
 
{{DTU-Denmark/mainCSS}}
 
{{DTU-Denmark/carouselCSS}}
 
{{DTU-Denmark/carouselCSS}}
<html>
+
<html lang="en">
 +
  <head>
 +
    <!-- Required meta tags -->
 +
    <meta charset="utf-8">
 +
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no, user-scalable=0">
 +
 
 +
 
 +
  <link rel="stylesheet" type="text/css" href="Template:DTU-Denmark/fontCSS?action=raw&ctype=text/css">
 +
 
 +
 
 +
 
 +
  </head>
 +
  <body>
 +
 
  
  
Line 23: Line 36:
 
 
  
<div class=" topimg pull-right sm-no-float col-md-8 ">
+
<div class=" topimg pull-right sm-no-float col-md-7 ">
 
 
  
  
<img src="https://static.igem.org/mediawiki/2019/4/41/T--DTU-Denmark--hpheader.svg" title="As science affects the world, the world affects science. This page describes what this project is going to bring to the world, and what we have learned and used from others" style="margin-top:75px;max-width:70%;margin-right:auto; margin-left:auto;display: block;
+
<img src="https://static.igem.org/mediawiki/2019/4/41/T--DTU-Denmark--hpheader.svg" alt="As science affects the world, the world affects science. This page describes what this project is going to bring to the world, and what we have learned and used from others" style="margin-top:75px;max-width:70%;margin-right:auto; margin-left:auto;display: block;
 
     height:auto;z-index:5;">
 
     height:auto;z-index:5;">
  
Line 35: Line 48:
 
        
 
        
  
       <div class="pull-left col-md-4 sm-text-center com-sm-12 ">
+
       <div class="pull-left col-md-5 sm-text-center com-sm-12 ">
 
<div class="team-heading"><h2>Integrated Human Practices</h2></div>
 
<div class="team-heading"><h2>Integrated Human Practices</h2></div>
 
<div class="team-overview" style="font-size: .9em;">
 
<div class="team-overview" style="font-size: .9em;">
Line 42: Line 55:
  
  
From the very beginning of our project, our team shared a common goal – we wanted to create something meaningful. To this end, we have been in contact with important stakeholders and their advice has shaped our approach, and the project direction.
+
From the very beginning of our project, our team shared a common goal – we wanted to create something meaningful. To this end, we have been in contact with important stakeholders and their advice has shaped our approach, and the project's direction.
 
</p>
 
</p>
  
Line 72: Line 85:
  
  
<div class="row flex-center sm-no-flex">
+
<div class="row flex-center sm-no-flex" style="margin-bottom:25px;">
  
 
 
Line 100: Line 113:
  
  
<div class="row flex-center sm-no-flex interlabspace">
+
<div class="row flex-center sm-no-flex">
  
 
<div class=" sm-no-float col-md-12 col-sm-12">
 
<div class=" sm-no-float col-md-12 col-sm-12">
Line 106: Line 119:
  
 
<figure>
 
<figure>
  <img src="https://static.igem.org/mediawiki/2019/2/2e/T--DTU-Denmark--iHPfig11.png" alt="Our stakeholder analysis led us to talk to 3 different companies: Zymergen, Novozymes, and Bolt Threads. We also talked to 3 fungal experts: Peter Richard (VTT, Finland), Jens Christian Frisvad (DTU, Denmark) and Jakob Blæsbjerg (DTU, Denmark). Additionally, we addressed the public by attending Science EXPO in Copenhagen, two biotechnology camps for high school students, and teaching synthetic biology in two high schools.
+
  <img src="https://static.igem.org/mediawiki/2019/1/15/T--DTU-Denmark--iHPmainfigurebigdone.png" alt="Our stakeholder analysis led us to talk to 3 different companies: Zymergen, Novozymes, and Bolt Threads. We also talked to 3 fungal experts: Peter Richard (VTT, Finland), Jens Christian Frisvad (DTU, Denmark) and Jakob Blæsbjerg (DTU, Denmark). Additionally, we addressed the public by attending Science EXPO in Copenhagen, two biotechnology camps for high school students, and teaching synthetic biology in two high schools.
 
" style="width:100%;    max-width: 650px;
 
" style="width:100%;    max-width: 650px;
 
     margin-right: auto;
 
     margin-right: auto;
Line 156: Line 169:
  
 
<br><br>
 
<br><br>
<h2>Click on the different bubbles to read more about what we learned from each stakeholder.</h2>
+
 
  
  
Line 178: Line 191:
  
  
<div class="row ">
+
 
 +
 
 +
<div class="row flex-center sm-no-flex">
  
 
 
      <div class="sm-no-float col-md-8" style="padding:25px">
+
 
 +
 
 +
 
 +
<div class="sm-no-float col-md-8 col-xs-12">
 +
 
 +
<h2>Click on the different bubbles to read more about what we learned from each stakeholder.</h2>
 +
 
 +
 
 +
 
  
  
 
<!-- Image Map Generated by http://www.image-map.net/ -->
 
<!-- Image Map Generated by http://www.image-map.net/ -->
<img style="padding:15px;margin: 0 auto;  max-width: 100%; height: auto;" src="https://static.igem.org/mediawiki/2019/9/91/T--DTU-Denmark--iHPmain.png"  border="0" width="800" height="944" orgWidth="800" orgHeight="944" usemap="#integratedhpfig3">
+
<img style="padding:15px;margin: 0 auto;  max-width: 100%; height: auto;" src="https://static.igem.org/mediawiki/2019/4/42/T--DTU-Denmark--newiHPMainThingy.png"  border="0" width="800" height="944" orgWidth="800" orgHeight="944" alt="Interactive figure of what we learned from our stakeholders: Bolt Threads, Jens Frisvad, Jakob Blæsbjerg, Zymergen, Peter Richards, and Novozymes" usemap="#integratedhpfig3">
  
 
<map name="integratedhpfig3">
 
<map name="integratedhpfig3">
Line 212: Line 235:
 
As Zymergen works with i.a. filamentous fungi and know what other biotechnology companies look for in promoters, they were able to provide us with a lot of valuable advice on how to approach our project.
 
As Zymergen works with i.a. filamentous fungi and know what other biotechnology companies look for in promoters, they were able to provide us with a lot of valuable advice on how to approach our project.
 
Among other things, they advised us to use the <i>Aspergillus niger</i> strain ATCC 1015 since this strain is commonly used in industry and contains an auxotrophic selection marker. <br>
 
Among other things, they advised us to use the <i>Aspergillus niger</i> strain ATCC 1015 since this strain is commonly used in industry and contains an auxotrophic selection marker. <br>
 +
Zymergen specialises in genetically engineering a broad range of non-standard hosts, and this directed us to open the software to be able to parse any given organism genome. Additionally, Zymergen is in the business of gene expression regulation/control, and a stable promoter ladder is therefore vital to their setup. Accordingly, we directed our experimental setup to also test the scalability of our synthetic promoters.
 
Additionally, we learned that the industry is interested in scarless assemblies between the promoter region and the start codon, as well as promoters that are active in the stationary phase. We took all of this into consideration when designing the software to create the promoters and when assembling the plasmids.</p>
 
Additionally, we learned that the industry is interested in scarless assemblies between the promoter region and the start codon, as well as promoters that are active in the stationary phase. We took all of this into consideration when designing the software to create the promoters and when assembling the plasmids.</p>
 
</div>
 
</div>
Line 291: Line 315:
 
<p>
 
<p>
 
Following the discussion with Zymergen, we decided to contact Jakob Blæsbjerg Hoof, associate professor at the Department of Biotechnology and Biomedicine. He told us that using a fluorescence marker was the easiest approach to select for transformants, and that we should add a secretion tag to the fluorescent protein in order to prevent accumulation inside the cell. This was later backed up by Bolt Threads.
 
Following the discussion with Zymergen, we decided to contact Jakob Blæsbjerg Hoof, associate professor at the Department of Biotechnology and Biomedicine. He told us that using a fluorescence marker was the easiest approach to select for transformants, and that we should add a secretion tag to the fluorescent protein in order to prevent accumulation inside the cell. This was later backed up by Bolt Threads.
Additionally, Blæsbjerg provided us with the ATCC 1015 <i>Aspergillus niger</i> strain that was used in the experiment as well as protocols for protoplasting and transformation.
+
Additionally, Blæsbjerg provided us with the ATCC 1015 <i>Aspergillus niger</i> strain, in addition to a protease-deficient variation (<i>prtT</i> KO), which were used in the experiment as well as protocols for protoplasting and transformation.
 
</p>
 
</p>
 
</div>
 
</div>
Line 306: Line 330:
 
</div>
 
</div>
  
 
+
</div>
  
 
<div class="column full_size" >
 
<div class="column full_size" >

Latest revision as of 02:27, 22 October 2019

As science affects the world, the world affects science. This page describes what this project is going to bring to the world, and what we have learned and used from others

Integrated Human Practices

From the very beginning of our project, our team shared a common goal – we wanted to create something meaningful. To this end, we have been in contact with important stakeholders and their advice has shaped our approach, and the project's direction.

Despite their relative anonymity, filamentous fungi are responsible for most of the industrially produced enzymes and are therefore exceptionally important to a lot of people’s everyday lives.
Project LEAP was founded in response to the acute lack of publicly available resources for synthetic biology work within filamentous fungi, and therefore aimed to expand the synthetic biology toolbox for these organisms.
Originally, the project aspired to create synthetic promoter libraries for filamentous fungi, yeast, and moss – but following valuable discussions with several companies and scientists, the team decided to develop a software that would enable the creation of promoters for any organism, and attempted to test the function of said software in Aspergilli.

Our stakeholder analysis led us to talk to 3 different companies: Zymergen, Novozymes, and Bolt Threads. We also talked to 3 fungal experts: Peter Richard (VTT, Finland), Jens Christian Frisvad (DTU, Denmark) and Jakob Blæsbjerg (DTU, Denmark). Additionally, we addressed the public by attending Science EXPO in Copenhagen, two biotechnology camps for high school students, and teaching synthetic biology in two high schools.
Fig. 1: Overview of the process for integrated human practices throughout the project.
The stakeholder analysis shows a square with four sections, which divides stakeholder’s into four categories: high interest and high power, high interest and low power, low interest, and high power, and low interest and low power.
Fig. 2: Stakeholder analysis

Stakeholder Analysis

In March, the team looked into the impact the project could have on different stakeholders, and therefore made a stakeholder analysis, as shown in figure 2. This stakeholder analysis reveals that companies such as Novozymes, Zymergen, and Bolt Threads are among the most important to our project, both in interest and power. This means that their opinions should be managed closely. Additionally, researchers such as Jens Frisvad (DTU, Denmark), Jakob Blæsbjerg (DTU, Denmark), and Peter Richard (VTT, Finland) could benefit from our project, making them important stakeholders. Although other iGEM teams do not have a lot of power, their interest could nevertheless be great and they should, therefore, be well informed. The public and the DTU BlueDot program will most likely not take much interest in the project as a promoter library can be a very technical concept and not immediately usable by non-specialists. However, as DTU BlueDot is a big sponsor of the team, they are important to keep satisfied.

Based on the stakeholder analysis, we decided to contact three different biotech companies; Novozymes, Zymergen, and Bolt Threads as they all work with genetically modified filamentous fungi. We asked them how our project could influence their work, and for suggestions regarding the experiments.

We also reached out to several scientists, including Jakob Blæsbjerg from DTU and Peter Richard from VTT (Technical Research Centre) in Finland. They provided us with protocols and advice on how to grow the fungi, and how to ensure we acquired reproducible and comparable results.

Even though the public is neither very powerful nor particularly interested in the project, at least according to our stakeholder analysis, we nevertheless decided to contact high schools in order to talk to young people about synthetic biology, our project and what good we believe it can do in the world. We also partook in several events: The annual UNF (Ungdommens Naturvidenskabelige Forening) Biotech Camp; Science Expo, a large science fair in Copenhagen; and the annual Biotech Academy Camp in order to increase their knowledge and interest in a topic like synthetic biology. This is described further on Education and Engagement.

The stakeholder analysis shows a square with four sections, which divides stakeholder’s into four categories: high interest and high power, high interest and low power, low interest, and high power, and low interest and low power.
Fig. 2: Stakeholder analysis

Click on the different bubbles to read more about what we learned from each stakeholder.

Interactive figure of what we learned from our stakeholders: Bolt Threads, Jens Frisvad, Jakob Blæsbjerg, Zymergen, Peter Richards, and Novozymes Zymergen Zymergen Peter Richards Peter Richards Novozymes Novozymes Bolt Threads Bolt Threads Jens Frisvad Jens Frisvad Jakob Blæsbjerg Jakob Blæsbjerg



The logos of our three biggest supporters, DTU Blue Dot, Novo Nordisk fonden and Otto Mønsted fonden The logos of all of our sponsors, DTU, BioNordica, Eurofins Genomics, Qiagen, NEB New England biolabs, IDT Integrated DNA technologies and Twist bioscience